The future of Orphazyme A/S is up in the air after regulators in the EU followed the stance of their US peers in rejecting arimoclomol, the Danish biotech's treatment for the ultra-rare disorder Niemann-Pick disease type C (NPC).
Orphazyme has been in close contact with the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?